1634 related articles for article (PubMed ID: 28376777)
21. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
[TBL] [Abstract][Full Text] [Related]
22. Preliminary study on the immunogenicity of a newly developed GCC Tdap vaccine and its protection efficacy against Bordetella pertussis in a murine intranasal challenge model.
Han SB; Kang KR; Huh DH; Lee HC; Lee SY; Kim JH; Hur JK; Kang JH
Clin Exp Vaccine Res; 2015 Jan; 4(1):75-82. PubMed ID: 25649262
[TBL] [Abstract][Full Text] [Related]
23. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India.
Sharma HJ; Parekh S; Pujari P; Shewale S; Desai S; Kawade A; Ravi M; Oswal J; James S; Mahantashetti N; Munshi R; Ghosh A; Rao V; Balsubramaniam S; Varughese P; Somshekhar A; Ginsburg AS; Rao H; Gautam M; Gairola S; Shaligram U
Expert Rev Vaccines; 2023; 22(1):278-287. PubMed ID: 36883291
[TBL] [Abstract][Full Text] [Related]
25. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
[TBL] [Abstract][Full Text] [Related]
27. A Randomized Controlled Trial of the Safety and Immunogenicity of Tetanus, Diphtheria, and Acellular Pertussis Vaccine Immunization During Pregnancy and Subsequent Infant Immune Response.
Halperin SA; Langley JM; Ye L; MacKinnon-Cameron D; Elsherif M; Allen VM; Smith B; Halperin BA; McNeil SA; Vanderkooi OG; Dwinnell S; Wilson RD; Tapiero B; Boucher M; Le Saux N; Gruslin A; Vaudry W; Chandra S; Dobson S; Money D
Clin Infect Dis; 2018 Sep; 67(7):1063-1071. PubMed ID: 30010773
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
Wood N; Nolan T; Marshall H; Richmond P; Gibbs E; Perrett K; McIntyre P
JAMA Pediatr; 2018 Nov; 172(11):1045-1052. PubMed ID: 30208475
[TBL] [Abstract][Full Text] [Related]
29. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
[TBL] [Abstract][Full Text] [Related]
30. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
31. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
[TBL] [Abstract][Full Text] [Related]
32. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A
Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.
Roduit C; Bozzotti P; Mielcarek N; Lambert PH; del Giudice G; Locht C; Siegrist CA
Infect Immun; 2002 Jul; 70(7):3521-8. PubMed ID: 12065491
[TBL] [Abstract][Full Text] [Related]
34. Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7-8 years of age.
Aase A; Herstad TK; Jørgensen SB; Leegaard TM; Berbers G; Steinbakk M; Aaberge I
Vaccine; 2014 Oct; 32(45):5931-6. PubMed ID: 25218299
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.
Blatter M; Friedland LR; Weston WM; Li P; Howe B
Vaccine; 2009 Jan; 27(5):765-72. PubMed ID: 19041352
[TBL] [Abstract][Full Text] [Related]
36. Seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women.
Sompagdee N; Anuwutnavin S; Phongsamart W; Senawong S; Umrod P; Robkhonburi A
Vaccine; 2020 Mar; 38(12):2725-2733. PubMed ID: 32070680
[TBL] [Abstract][Full Text] [Related]
37. Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.
Aase A; Herstad TK; Merino S; Bolstad M; Sandbu S; Bakke H; Aaberge IS
Clin Vaccine Immunol; 2011 Aug; 18(8):1269-74. PubMed ID: 21677109
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam.
Maertens K; Hoang TT; Nguyen TD; Caboré RN; Duong TH; Huygen K; Hens N; Van Damme P; Dang DA; Leuridan E
Clin Infect Dis; 2016 Dec; 63(suppl 4):S197-S204. PubMed ID: 27838673
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
